Please use this identifier to cite or link to this item:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

AuthorsMaia, Catarina; Puig, Noemi; Cedena, Maria-Teresa; Vázquez, Iria; Chillón, M. del Carmen; Calasanz, Mª Jose; García-Sanz, Ramón; González, Marcos CSIC ORCID ; Gutiérrez, Norma Carmen; Martínez-López, Joaquín; Pérez, José J.; Merino, Juana; Moreno, Cristina; Burgos, Leire; Alignani, Diego; Prosper, Felipe; Matarraz, Sergio; Orfao, Alberto CSIC ORCID ; Oriol, Albert; Teruel, Ana-Isabel; Paz, Raquel de; Arriba, Felipe de; Hernandez, Miguel T.; Palomera, Luis; Martinez, Rafael; Rosiñol, Laura; Mateos, Maria Victoria; Lahuerta, Juan José; Bladé, Joan; San Miguel, Jesús F. CSIC ORCID; Paiva, Bruno
Issue Date2020
PublisherAmerican Society of Hematology
CitationBlood 135(26): 2375–2387 (2020)
AbstractRisk of developing myelodysplastic syndrome (MDS) is significantly increased in both multiple myeloma (MM) and monoclonal gammopathy of undetermined significance, suggesting that it is therapy independent. However, the incidence and sequelae of dysplastic hematopoiesis at diagnosis are unknown. Here, we used multidimensional flow cytometry (MFC) to prospectively screen for the presence of MDS-associated phenotypic alterations (MDS-PA) in the bone marrow of 285 patients with MM enrolled in the PETHEMA/GEM2012MENOS65 trial (#NCT01916252). We investigated the clinical significance of monocytic MDS-PA in a larger series of 1252 patients enrolled in 4 PETHEMA/GEM protocols. At diagnosis, 33 (11.6%) of 285 cases displayed MDS-PA. Bulk and single-cell–targeted sequencing of MDS recurrently mutated genes in CD34+ progenitors (and dysplastic lineages) from 67 patients revealed clonal hematopoiesis in 13 (50%) of 26 cases with MDS-PA vs 9 (22%) of 41 without MDS-PA; TET2 and NRAS were the most frequently mutated genes. Dynamics of MDS-PA at diagnosis and after autologous transplant were evaluated in 86 of 285 patients and showed that in most cases (69 of 86 [80%]), MDS-PA either persisted or remained absent in patients with or without MDS-PA at diagnosis, respectively. Noteworthy, MDS-associated mutations infrequently emerged after high-dose therapy. Based on MFC profiling, patients with MDS-PA have altered hematopoiesis and T regulatory cell distribution in the tumor microenvironment. Importantly, the presence of monocytic MDS-PA at diagnosis anticipated greater risk of hematologic toxicity and was independently associated with inferior progression-free survival (hazard ratio, 1.5; P = .02) and overall survival (hazard ratio, 1.7; P = .01). This study reveals the biological and clinical significance of dysplastic hematopoiesis in newly diagnosed MM, which can be screened with moderate sensitivity using cost-effective MFC.
DescriptionOn behalf of the PETHEMA/GEM Cooperative Group.
Publisher version (URL)
Appears in Collections:(IBMCC) Artículos

Files in This Item:
File Description SizeFormat
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
Show full item record
Review this work

Google ScholarTM




WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.